title: Office-based treatment of laryngeal papillomatosis with percutaneous injection of cidofovir.
abstract: OBJECTIVE
  Our aim was to report our experience with office-based treatment of severe laryngeal papillomatosis with percutaneous injection of cidofovir in a case series of 5 patients.
  
  
  METHODS
  We conducted a retrospective review of a case series in a tertiary academic care voice disorders clinic. Adult patients with papillomas of the vocal cords and anterior commissure received percutaneous injection using a point-touch technique. Clinical improvement or remission of the papillomatosis was noted.
  
  
  RESULTS
  Before initiation of office treatments, patients required direct laryngoscopy and CO(2) laser ablation of papillomas on average every 2.8 months. There were no complications related to the injection technique. During a treatment period of 7 to 16 months (mean 12 months), a significant reduction in the volume of papillomatosis was achieved in all patients. One patient received 2 treatments and another received 1 treatment in the operating room for final clearance of papillomas.
  
  
  CONCLUSIONS
  Office-based treatment of adult patients with anterior laryngeal papillomatosis using percutaneous injection of cidofovir reduces the need for repeated direct laryngoscopy and laser ablation under general anesthesia.
  
  
  CONCLUSIONS
  Percutaneous injection treatment with cidofovir is a useful adjunct to direct laryngoscopy and laser ablation in the treatment of laryngeal papillomatosis.
authors.affiliation: Division of Head and Neck Surgery, UCLA School of Medicine, 90095, USA. dchhetri@ucla.edu
authors.forename: Dinesh K
authors.initials: DK
authors.lastname: Chhetri
authors.forename: Joel H
authors.initials: JH
authors.lastname: Blumin
authors.forename: Nina L
authors.initials: NL
authors.lastname: Shapiro
authors.forename: Gerald S
authors.initials: GS
authors.lastname: Berke
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage* / Q000031:analogs & derivatives; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D007828:Laryngoscopy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage*; D010212:Papilloma / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D012494:Sampling Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir